Maytenhoiridosides A and B, two new iridoid glycosides from the branches of Maytenus hookeri

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-07-01 DOI:10.1016/j.phytol.2024.06.007

Huijing Lv , Qinghong Kong , Changwei Song , Jiawei Yang , Lingjie Meng

引用次数: 0

Abstract

Two new iridoid glycosides, maytenhoiridosides A (1) and maytenhoiridosides B (2), along with three known compounds (3–5), were isolated from the branches of Maytenus hookeri. Their chemical structures were elucidated by HR-ESI-MS, 1D and 2D-NMR spectra, acid hydrolysis analysis, and comparison with literature data. Among the isolated compounds, compound 5 exhibited significant cytotoxic activity against the HCT-116, SKOV3 and SK-Hep-1 cells, with IC₅₀ values of 9.49±1.40, 34.66±1.48 and 12.66±3.32 µM, respectively, while the others showed weak or no activity at 50 μM.

Abstract Image

查看原文本刊更多论文

Maytenhoiridosides A 和 B，两种新的鸢尾甙，来自 Maytenus hookeri 的枝条

从钩吻马钱子（Maytenus hookeri）的枝条中分离出了两种新的鸢尾甙，即马钱子甙 A（1）和马钱子甙 B（2），以及三种已知化合物（3-5）。通过 HR-ESI-MS、1D 和 2D-NMR 光谱、酸水解分析以及与文献数据的比较，阐明了这些化合物的化学结构。在分离出的化合物中，化合物 5 对 HCT-116、SKOV3 和 SK-Hep-1 细胞具有显著的细胞毒活性，IC50 值分别为 9.49±1.40、34.66±1.48 和 12.66±3.32 µM，而其他化合物在 50 μM 时活性较弱或无活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.